![]() |
市场调查报告书
商品编码
1722404
2025 年至 2033 年放射肿瘤学市场报告(按类型、技术、应用、最终用户和地区)Radiation Oncology Market Report by Type, Technology, Application, End User, and Region 2025-2033 |
2024 年全球放射肿瘤学市场规模达 86 亿美元。展望未来, IMARC Group预计到 2033 年市场规模将达到 149 亿美元,2025-2033 年期间的成长率 (CAGR) 为 6.3%。技术进步、癌症发生率上升、对肿瘤放射认识的提高、政府倡议和合作、新疗法的监管批准以及个人化医疗的趋势是促进市场成长的一些因素。
主要市场驱动因素:放射肿瘤学市场的成长受到多种因素的推动,包括全球癌症发生率的激增。对有效和准确的治疗方法的高需求促使影像引导放射治疗和质子治疗的发展,这进一步刺激了市场成长。另一个趋势是老年人口数量的增加,从统计数据来看老年人口更容易罹患癌症。此外,对医疗中心发展的投资(特别是在发展中国家)以及政府和私人癌症筛检和预防措施的实施正在推动放射肿瘤学市场份额的成长。与此相符的是,研究机构和公司正在积极联手开发创新放射疗法,这有利于市场成长。
主要市场趋势:放射肿瘤学市场的主要趋势之一是向低分次和超低分次疗法转变,即在几个疗程中给予更高剂量的放射线。这种方式方便了患者,也减少了医疗支出。此外,人工智慧 (AI) 和机器学习 (ML) 在治疗计划系统中的使用正在增长,产生了更量身定制的管理模式,与传统系统相比,可以更精确地将辐射传送到受影响的位置,同时减少对周围健康组织的损害,从而加速市场增长。此外,多模态治疗继续带来福音,将放射疗法与手术、化疗和免疫疗法等其他疗法结合,进一步改善治疗效果。除此之外,治疗计划的日益增长的趋势正在推动放射肿瘤学市场的成长,该趋势旨在最大限度地减少治疗对患者生活品质的影响。
地理趋势:目前,北美处于世界放射肿瘤学市场的前沿。该地区占据主导地位的因素有很多,包括先进的医疗保健基础设施、高额的医疗保健支出以及知名设备製造商的存在。该地区强大的市场地位也源于积极的研究和高新技术采用率,例如质子治疗中心。此外,欧洲市场的扩张受到严格的医疗政策和大规模公共卫生计划的推动,这些政策和计划强调癌症治疗品质和可近性的重要性。根据放射肿瘤学市场分析,亚太地区是一个新兴地区。医疗保健支出不断增加,人们对癌症的认识也日益增强。中国和印度等国家的医疗设施正变得越来越先进。
竞争格局:市场竞争格局的特征是主要放射肿瘤学公司的存在,例如 Accuray Incorporated、Becton Dickinson and Company、Canon Inc.、Elekta、Hitachi Ltd.、Icad Inc.、Ion Beam Applications、Isoray Inc.、Mevion Medical Systems Inc.、Nevordion (Ion Beam Applications、Isoray Inc.、Mjion Medical Systems Inc.、Nevordion (Siada) Inc. AG)、ViewRay 等。
挑战与机会:放射肿瘤学市场面临先进放射治疗系统相关成本高昂等挑战,可能限制欠富裕地区的市场渗透。监管障碍也带来了重大挑战,因为获得新技术的批准可能既费时又昂贵。此外,新兴市场缺乏熟练的专业人员,这阻碍了先进疗法的采用。然而,这些挑战也带来了机会。例如,开发具有成本效益的放射治疗机可以帮助渗透低收入市场。针对肿瘤护理提供者的教育措施和培训计划可以缓解合格专业人员的短缺。
技术进步
影响全球放射肿瘤学市场的主要因素之一是不断进步的技术。包括调强放射治疗 (IMRT) 和影像导引放射治疗 (IGRT) 在内的技术发展重新定义了癌症的治疗,能够更准确地瞄准肿瘤,同时最大程度地减少对其他健康身体细胞的损害。例如,IMRT 所施加的辐射剂量具有不同的强度。该技术使肿瘤科医师能够根据肿瘤的复杂形状调整放射束,同时尽量减少对周围健康组织的破坏。另一方面,IGRT 利用 CT 扫描或 MRI 等专门的影像技术在每次治疗前确定肿瘤的确切位置。除了产生高品质的肿瘤影像外,IGRT 还提供测试位置验证和执行多条机械化辐射束的治疗。此外,横向治疗的进步导致了质子治疗的发明。该疗法使用高能量质子取代传统的X射线进行放射治疗,可以实现更高的剂量集中度,同时将副作用降至最低。例如,2024年,一个主要来自核武相关科学机构的中国研究小组设计了一种名为「闪光」的强力辐照系统。该系统能够施加超高能量辐射,并有可能改变传统的放射疗法。
癌症发生率上升
全球放射肿瘤学市场主要受到世界各地癌症发生率增加的推动,尤其是在发展中国家。根据世界卫生组织(WHO)最新的全球癌症发生率报告,2022年印度新增癌症病例超过141万例,癌症死亡人数超过91万例。乳癌是全球最常见的癌症发生率指标,占所有新发癌症的十分之一以上。随着年龄的增长,癌症的发生率也会上升;此外,长期已知的机会的变化和长期存在的环境因素也是额外的成长因素。癌症患者数量的不断增长也推动了放射肿瘤学的需求,预计癌症将成为国际上最常见的死亡原因之一。
提高意识和政府倡议
对早期癌症诊断和治疗重要性的认识不断提高,以及公共部门积极主动地分配资源以确保癌症患者得到高品质的护理,正在推动全球放射肿瘤学的发展。各种非政府组织 (NGO) 和国际组织正在实施多项公众意识计划和活动,以提高患者对癌症和放射治疗服务日益增长的需求的认识。政府卫生机构也正在投资癌症控制、设施开发和支付计划,以增强获得放射服务的机会并减轻癌症负担,这进一步推动了放射肿瘤学市场前景。
The global radiation oncology market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.3% during 2025-2033. Technological advancements, rising cancer incidence, increasing awareness regarding oncology radiation, government initiatives, and collaborations, regulatory approvals for new therapies, and the trend towards personalized medicine are some of the factors fostering the market growth.
Major Market Drivers: The radiation oncology market growth is fueled by the factors, including the surging prevalence of cancer across the globe. The high demand for effective and accurate treatment methods prompts the development of image-guided radiation therapy and proton therapy, which is further stimulating the market growth. Another trend is also the rise in the number of geriatric population that is statistically more prone to cancer. In addition, investments in the development of medical centers, especially in developing countries, and availability of government and private cancer screening and prevention initiatives are driving the radiation oncology market share. In line with this, research institutions and companies are actively joining forces for the development of innovative radiation therapies, which is favoring the market growth.
Key Market Trends: One of the key radiation oncology market trends is the shift toward hypofractionated and ultra-hypofractionated therapies, in which higher doses of radiation are given over few sessions. This approach is convenient for patients and reduces medical expenditures. Moreover, the use of artificial intelligence (AI) and machine learning (ML) in treatment planning systems is growing, producing more tailored administration patterns which deliver radiation more precisely to the affected location than traditional systems while reducing damage to surrounding healthy tissue, which is accelerating the market growth. Furthermore, multimodality treatments continue to provide a boon, combining radiation therapy with other treatments like surgery, chemotherapy, and immunotherapy, which further improves therapeutic outcomes. Apart from this, the growing trend towards therapeutic scheduling that minimizes the impact of the therapy on the patient's quality of life is driving the radiation oncology market growth.
Geographical Trends: At present, North America is at the forefront of the world's radiation oncology market. Several factors contribute to this region's dominance, including the advanced healthcare infrastructure, high healthcare spending, and the presence of prominent device manufacturers. The region's strong market position also stems from research being pursued aggressively and high rates of new technology adoption, such as proton therapy centers. Moreover, Europe's market expansion is driven by stringent healthcare policies and large-scale public health programs that stress the importance of cancer treatment quality and accessibility. As per the radiation oncology market analysis, the Asia-Pacific is an up-and-coming region. Healthcare spending is on the rise, and cancer awareness is growing. The healthcare facilities are becoming more advanced in countries such as China and India.
Competitive Landscape: The competitive landscape of the market is characterized by the presence of key radiation oncology companies, such as Accuray Incorporated, Becton Dickinson and Company, Canon Inc., Elekta, Hitachi Ltd., Icad Inc., Ion Beam Applications, Isoray Inc., Mevion Medical Systems Inc., Nordion (Canada) Inc. (Sotera Health), P-Cure Ltd., Varian Medical Systems Inc. (Siemens Healthineers AG), ViewRay, etc.
Challenges and Opportunities: The radiation oncology market faces challenges such as high costs associated with advanced radiation therapy systems, which can limit market penetration in less affluent regions. Regulatory hurdles also pose significant challenges, as gaining approval for new technologies can be time-consuming and costly. Moreover, there is a shortage of skilled professionals in emerging markets, which hampers the adoption of advanced therapies. However, these challenges also present opportunities. For example, the development of cost-effective radiation therapy machines can help penetrate low-income markets. Educational initiatives and training programs for oncology care providers can alleviate the shortage of qualified professionals.
Technological Advancements
One of the major factors influencing the global radiation oncology market is the continually advancing technology. Technological development, including the creation of intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), have redefined the treatment of cancer, enabling more accurate targeting of tumors with minimal damage to other healthy body cells. For example, IMRT employs varied intensities in the radiation doses it administers. This technology enables oncologists to conform the radiation beams according to the complicated shape of the tumor with minimal destruction of surrounding healthy tissues. IGRT, on the other hand, utilizes specialized imagining such as CT scans or MRIs to identify the tumor's exact location before each treatment session. In addition to producing high quality images of the tumor, IGRT offers test position verification and treatment carrying out several mechanized radiation beams. Further, lateral therapy advancements have resulted in the invention of proton therapy. This therapy administers radiation with high-energy protons instead of traditional x-rays, allowing superior dose concentration with minimal side effects. For instance, in 2024, a powerful irradiation system called the Flash was designed by a Chinese research group mainly from nuclear weapons related scientific institutions. The system is capable of administering ultra-high energy radiation and has the potential to transform conventional radiotherapy.
Rising Incidence of Cancer
The global radiation oncology market is primarily fueled by an increase in cancer occurrence across the world, mainly in developing countries. According to the most recent report on the global occurrence of the disease by the World Health Organization (WHO), there were over 14.1 lakh new cancer instances and more than 9.1 lakh cancer-related deaths in India in 2022. Breast cancer was the most frequently identified measure of global occurrence of the disease, accounting for more than one-tenth of all new illnesses. The prevalence of cancer rises as people age; moreover, a change in long-known chances and the presence of longstanding environmental are additional growth factors. The radiation oncology demand is also boosted by the growing number of cancer patients, which is predicted to be one of the most common causes of death internationally.
Increasing Awareness and Government Initiatives
Rising knowledge about the importance of early cancer diagnosis and treatment, as well as public sector proactiveness and allocation of resources to ensure that cancer patients receive high-quality care, are driving the growth of radiation oncology globally. Several public awareness programs and campaigns are being implemented by various non-governmental organizations (NGOs) and international organizations to boost patient awareness of cancer and the rising need for radiation therapy services. Government health agencies are also investing in cancer control, facilities development, and payment schemes to enhance access to radiation services and reduce the cancer burden, which is further driving the radiation oncology market outlook.
External beam radiation therapy (EBRT) accounts for the majority of the market share
North America leads the market, accounting for the largest radiation oncology market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.